Wentworth Douglass Hospital

Hence, this research aims to establish the correlation between cardiac troponin and results in acute ischemic stroke (AIS) patients with heart failure. It examines 367 AIS patients stratified into 2 age groups: 65-74 years and ≥75 years. According to the findings, independent ambulation at admission or discharge signifies less severe strokes National Institutes of Health Stroke Scale. That is, the characteristics that are important for the stroke severity in patients of different ages are different: while the patients aged 75 and older, the important predictors are peripheral vascular disease and increased heart rate, the stroke severity in the younger age is predicted by smoking history and increased serum creatinine. Further, the article examines the value of troponin in a consecutive series of 1145 AIS patients and demonstrates that increased troponin is an independent predictor of in-hospital mortality. Mortality of the troponin-positive patients is significantly high with an odds ratio of 4.28. Moreover, the second trial on 200 AIS patients demonstrated that the cardiac troponin isoforms size is an independent predictor of major adverse cardiac events, odds ratio of 9.76. A study of 151,972 reaffirms the relationship between high troponin levels, increased stroke severity, and worse clinical prognosis. In conclusion, the current work fosters the significance of evaluating cardiac troponin in AIS patients with heart failure for enhanced mortality and adverse cardiovascular events' risk estimation.

Abstract Background Valve replacement, often involving cardiopulmonary bypass (CPB), can induce myocardial ischaemia and reperfusion injury despite cardioplegia. Remote ischaemic preconditioning (RIPC), involving brief ischaemia/reperfusion cycles in a remote limb, has emerged as a potential strategy to mitigate this injury. While some trials suggest benefits, others show no effect. This meta-analysis investigates the protective effects of RIPC in patients undergoing isolated valve replacement surgery, considering its impact on myocardial injury markers. Purpose This meta-analysis aims to resolve conflicting findings regarding the efficacy of RIPC in valve replacement. By synthesising available evidence, we seek to determine if RIPC reduces myocardial injury and has protective pulmonary and renal effects. Our study will help clinicians make informed clinical decisions and potentially improve patient outcomes. Methodology A comprehensive search of major databases like PubMed, Scopus, Embase, Cochrane, and Google Scholar was conducted to retrieve eligible studies. The inverse variance random-effects model was used to generate pooled effects estimates of outcomes as mean difference (MD) and standard mean difference (SMD) and risk ratios (RR) with a 95% confidence interval. Results 9 studies were included in the analysis, with 1269 patients (636: RIPC; 633: Control). Remote ischaemic preconditioning (RIPC) significantly reduced CK-MB levels [SMD: -0.24; 95% CI: -0.41, -0.06; p = 0.008] and cTnI levels [SMD: -2.09; 95% CI: -3.15, -1.04; p = 0.0001], indicating myocardial protection. Additionally, RIPC significantly decreased the duration of invasive ventilation [MD: -0.78; 95% CI: -1.48, -0.08; p = 0.03]. However, it had no significant effect on the risk of acute kidney injury (AKI) [RR: 0.95; 95% CI: 0.80, 1.13; p = 0.57], ICU stay duration [MD: -2.60; 95% CI: -9.35, 4.14; p = 0.45], or hospital length of stay [MD: -0.30; 95% CI: -0.62, 0.01; p = 0.06]. Conclusion RIPC significantly reduces myocardial injury and the duration of the invasive ventilation required in valve replacement, demonstrating cardiopulmonary protective effects. However, we found no significant impact on clinical outcomes such as AKI, ICU stay, or hospital length of stay. This discrepancy suggests that while RIPC may offer biochemical myocardial protection, its impact on broader clinical outcomes requires further investigation, potentially focusing on specific patient subgroups.

BackgroundDirect-acting oral anticoagulants (DOACs) are recommended to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, DOAC dosing inconsistent with FDA-approved product labels is common and associated with poor clinical outcomes.ObjectivesIdentify DOAC dosing inconsistent with FDA-approved product labels in ambulatory care patients with NVAF; identify variables associated with dosing lower and higher than label.DesignRetrospective analysis using electronic health records from nine US healthcare systems.PatientsAdults with NVAF receiving DOAC therapy in 2022.Main MeasuresRates of label-inconsistent dosing; multivariable regression analysis to identify demographic and clinical variables associated with dosing lower and higher than label.Key ResultsAmong 51,128 NVAF patients (56.1% male, 94.3% White, mean [SD] age 73.5 [10.5] years), 5008 (9.8%) were prescribed label-inconsistent doses of DOACs (6.8% lower and 3.0% higher than label). Age ≥ 75 years, renal impairment, and hypertension were significantly associated with inconsistent dosing both higher and lower than label. Female sex and higher weight were significantly associated with dosing lower than label, as were heart failure, vascular or liver disease, and bleeding history. Dosing higher than label was significantly associated with male sex, race (African American/Black), weight < 60 kg, and use of drugs with potential drug-drug interactions. When prescribed by primary care physicians, DOAC doses were 37% (95% CI, 27–49%) more likely to be lower than label and 30% (95% CI, 16–46%) more likely to be higher than label than when prescribed by cardiologists or electrophysiologists. Label-inconsistent dosing varied (6.7 to 15.8%) across participating systems.ConclusionsDOAC dosing inconsistent with label varied by demographics, clinical characteristics, prescriber specialty, and healthcare system, suggesting a need to monitor and assess dosing decisions in NVAF. Identification of variables associated with dosing inconsistencies may enable targeted interventions to ensure label-consistent dosing in vulnerable populations.

Introduction: Acute pancreatitis is a well known entity that has been extensively studied. But there is limited data with regard to pancreatitis in patients with a history of solid organ transplantation (SOT). The objective of our study was to assess the outcomes of acute pancreatitis in patients with a history of SOT. Methods: The National Inpatient Sample (NIS) database from 2016 was used for this study. Patients with age less than 18 years or those without a diagnosis of acute pancreatitis were excluded. The exposure variable was a history of SOT (kidney, heart, lung, liver or intestinal transplantation). Mortality was the primary outcome. Length of stay in the hospital and total charges for the hospitalization were the secondary outcomes. Categorical and continuous outcomes were analyzed with logistic regression and linear regression respectively. Statistical Analysis System (SAS) was used to analyze the data. Results: A total of 90,796 patient encounters for acute pancreatitis were included, of which 130 had a history of SOT. Mean age was 53.34 years and 48.34% were females. There was no significant difference in mortality between patients with and without a history of SOT (P-value: 0.53). Length of stay was significantly higher for patients with SOT compared to those without SOT (7.33 days vs 5.45 days; P-value: 0.006). On multiple regression analysis, history of SOT was associated with an increase in LOS by 1.43 days (P-values 0.03) (Table 1). Other factors associated with LOS along with SOT on multiple regression analysis were age, female sex, race, smoking, obesity, treatment at a teaching hospital, patients transferred in from another hospital, and admission on a weekend. This longer length of stay translated into higher mean total charges for the hospital stay as well ($187, 936 vs $55, 251, P-value: 0.009). Conclusion: Although a history of SOT was not associated with higher mortality due to acute pancreatitis, it was associated with a significantly longer length of stay in the hospital and total charges for the hospitalization for acute pancreatitis. Further research into factors contributing to the longer stay is warranted to identify areas of improvement. Table 1. - Factors affecting the length of stay for acute pancreatitis on multiple regression analysis Variable ParameterEstimate StandardError P-value Solid organ transplantation 1.43305 0.67630 0.0341 AGE 0.02655 0.00147 < .0001 Female sex -0.36369 0.05051 < .0001 Race 0.07122 0.02209 0.0013 Active smoker -0.60484 0.16426 0.0002 Obesity 0.23967 0.07064 0.0007 Teaching Hospital 0.98948 0.03737 < .0001 Admission on weekend -0.14529 0.05736 0.0113 Transferred in from a different hospital 1.91848 0.07312 < .0001